AstraZeneca's Datroway boosts survival in advanced breast cancer trial

AstraZeneca and Daiichi Sankyo's precision drug Datroway demonstrated significant improvement in overall and progression-free survival in a late-stage trial for aggressive, advanced breast cancer patients unsuitable for immunotherapy, marking a potential 'inflection point' for this high-need population. This positive data, which led to a nearly 1% rise in AstraZeneca's shares, is expected to facilitate broader regulatory approvals and expand the market for the antibody-drug conjugate.

Analysis

Oct 6 (Reuters) - AstraZeneca (AZN.L) and Daiichi Sankyo's (4568.T) precision drug Datroway improved survival prospects in patients with an advanced form of breast cancer in a late-stage trial, the drugmakers said on Monday, paving the way for broader approvals. The trial was for patients with a type of aggressive and advanced breast cancer for whom immunotherapy was not an option, AstraZeneca said. The treatment was given early and compared with chemotherapy. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here. Advertisement · Scroll to continue The company added that Datroway was the first therapy to significantly improve overall survival in this group, and that it also significantly improved progression-free survival and met the dual main goal of the study. "We expect today's results will mark an inflection point in the treatment of these patients who have the poorest prognosis of any type of breast cancer and urgently need better options," said Susan Galbraith, AstraZeneca's executive vice president, Oncology Haematology R&D. Datroway belongs to a class of medicines called antibody-drug conjugates, also known as "guided-missiles" because they are designed to target only cancer cells while sparing healthy cells, unlike conventional chemotherapy. Advertisement · Scroll to continue It works by targeting the TROP2 protein found on the surface of tumour cells of many types of cancer, and is already approved for treating a form of breast cancer and a type of lung cancer. AstraZeneca, whose shares rose nearly 1% in early trading, said the companies would share detailed results of the latest trial with regulators and present them at an upcoming, unspecified medical conference. Reporting by Pushkala Aripaka in Bengaluru; Editing by Nivedita Bhattacharjee and Mrigank Dhaniwala Our Standards: The Thomson Reuters Trust Principles. AstraZeneca (AZN) and its partner Daiichi Sankyo have announced positive top-line results from a late-stage trial for their drug, Datroway. The study successfully met its dual primary endpoints, demonstrating a statistically significant improvement in both overall survival and progression-free survival for patients with an aggressive, advanced form of breast cancer. This is a notable clinical milestone, as Datroway is the first therapy to show a significant overall survival benefit in this specific patient group, which has limited treatment options and cannot receive immunotherapy. The drug, an antibody-drug conjugate (ADC) targeting the TROP2 protein, is now positioned for broader regulatory approvals, which would expand its market beyond current indications. The market's initial reaction was positive, with AstraZeneca's shares rising nearly 1% in early trading, underscoring the perceived value of this development for the company's oncology franchise.

Key Decisions for Investors

• The successful late-stage trial for Datroway significantly de-risks a key asset in AstraZeneca's oncology pipeline, strengthening the case for future revenue growth and supporting a constructive view on the stock.
• Investors should monitor for the forthcoming presentation of detailed trial data at a medical conference, as the specific magnitude of the survival benefit will be critical for assessing the drug's full commercial potential versus standard chemotherapy.
• While the news is a clear positive catalyst, the ultimate financial upside is contingent on the timing and success of regulatory submissions and subsequent market adoption, which remain key variables to track.